Eli Lilly and Co
NYSE:LLY

Watchlist Manager
Eli Lilly and Co Logo
Eli Lilly and Co
NYSE:LLY
Watchlist
Price: 813.48 USD 1.48% Market Closed
Market Cap: 772.3B USD
Have any thoughts about
Eli Lilly and Co?
Write Note

Intrinsic Value

The intrinsic value of one LLY stock under the Base Case scenario is 375.83 USD. Compared to the current market price of 813.48 USD, Eli Lilly and Co is Overvalued by 54%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

LLY Intrinsic Value
375.83 USD
Overvaluation 54%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Eli Lilly and Co

Intrinsic Value History
Dive into the past to invest in the future

Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start now and learn if your stock is truly undervalued or overvalued!

Start Valuation
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
LLY
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for LLY cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Despite the significant buzz around tirzepatide and other diabetes products, their high development and marketing costs could erode profitability if insurance reimbursement or pricing pressures intensify, particularly in today’s cost-conscious healthcare environment.

Eli Lilly’s reliance on blockbuster treatments like Trulicity exposes it to heightened competitive threats and patent cliffs—any new biosimilar entrants or patent challenges could substantially reduce revenue streams faster than anticipated.

R&D setbacks in the high-risk neurology and oncology segments could stall the pipeline’s momentum, especially if trials fail to demonstrate clear clinical benefits, jeopardizing future growth and investor confidence.

Bull Theses

Tirzepatide’s rapid approvals and robust clinical outcomes in diabetes and obesity treatments position Eli Lilly to capture valuable market share in a high-growth therapeutic area, protecting long-term revenue streams.

A well-diversified pipeline, including Alzheimer’s candidates like donanemab, aligns with major unmet clinical needs and underscores Eli Lilly’s capacity to deliver innovative treatments that command premium pricing.

The company’s strategic partnerships and acquisitions, such as those aimed at expanding the oncology platform, strengthen its pipeline while distributing R&D risk across multiple promising therapeutic classes.

Show More Less
How do you feel about LLY?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Eli Lilly and Co

Provide an overview of the primary business activities
of Eli Lilly and Co.

What unique competitive advantages
does Eli Lilly and Co hold over its rivals?

What risks and challenges
does Eli Lilly and Co face in the near future?

Has there been any significant insider trading activity
in Eli Lilly and Co recently?

Summarize the latest earnings call
of Eli Lilly and Co.

What significant events have occurred
in Eli Lilly and Co over the past months?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Eli Lilly and Co.

Provide P/S
for Eli Lilly and Co.

Provide P/E
for Eli Lilly and Co.

Provide P/OCF
for Eli Lilly and Co.

Provide P/FCFE
for Eli Lilly and Co.

Provide P/B
for Eli Lilly and Co.

Provide EV/S
for Eli Lilly and Co.

Provide EV/GP
for Eli Lilly and Co.

Provide EV/EBITDA
for Eli Lilly and Co.

Provide EV/EBIT
for Eli Lilly and Co.

Provide EV/OCF
for Eli Lilly and Co.

Provide EV/FCFF
for Eli Lilly and Co.

Provide EV/IC
for Eli Lilly and Co.

Show me price targets
for Eli Lilly and Co made by professional analysts.

What are the Revenue projections
for Eli Lilly and Co?

How accurate were the past Revenue estimates
for Eli Lilly and Co?

What are the Net Income projections
for Eli Lilly and Co?

How accurate were the past Net Income estimates
for Eli Lilly and Co?

What are the EPS projections
for Eli Lilly and Co?

How accurate were the past EPS estimates
for Eli Lilly and Co?

What are the EBIT projections
for Eli Lilly and Co?

How accurate were the past EBIT estimates
for Eli Lilly and Co?

Compare the revenue forecasts
for Eli Lilly and Co with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Eli Lilly and Co and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Eli Lilly and Co against its competitors.

Analyze the profit margins
(gross, operating, and net) of Eli Lilly and Co compared to its peers.

Compare the P/E ratios
of Eli Lilly and Co against its peers.

Discuss the investment returns and shareholder value creation
comparing Eli Lilly and Co with its peers.

Analyze the financial leverage
of Eli Lilly and Co compared to its main competitors.

Show all profitability ratios
for Eli Lilly and Co.

Provide ROE
for Eli Lilly and Co.

Provide ROA
for Eli Lilly and Co.

Provide ROIC
for Eli Lilly and Co.

Provide ROCE
for Eli Lilly and Co.

Provide Gross Margin
for Eli Lilly and Co.

Provide Operating Margin
for Eli Lilly and Co.

Provide Net Margin
for Eli Lilly and Co.

Provide FCF Margin
for Eli Lilly and Co.

Show all solvency ratios
for Eli Lilly and Co.

Provide D/E Ratio
for Eli Lilly and Co.

Provide D/A Ratio
for Eli Lilly and Co.

Provide Interest Coverage Ratio
for Eli Lilly and Co.

Provide Altman Z-Score Ratio
for Eli Lilly and Co.

Provide Quick Ratio
for Eli Lilly and Co.

Provide Current Ratio
for Eli Lilly and Co.

Provide Cash Ratio
for Eli Lilly and Co.

What is the historical Revenue growth
over the last 5 years for Eli Lilly and Co?

What is the historical Net Income growth
over the last 5 years for Eli Lilly and Co?

What is the current Free Cash Flow
of Eli Lilly and Co?

Discuss the annual earnings per share (EPS)
trend over the past five years for Eli Lilly and Co.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Eli Lilly and Co

Current Assets 32.7B
Cash & Short-Term Investments 3.4B
Receivables 13.3B
Other Current Assets 16B
Non-Current Assets 46B
Long-Term Investments 3.2B
PP&E 17.1B
Intangibles 11.9B
Other Non-Current Assets 13.7B
Current Liabilities 28.4B
Accounts Payable 3.2B
Accrued Liabilities 13.6B
Other Current Liabilities 11.5B
Non-Current Liabilities 36.1B
Long-Term Debt 28.5B
Other Non-Current Liabilities 7.6B
Efficiency

Free Cash Flow Analysis
Eli Lilly and Co

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Eli Lilly and Co

Revenue
45B USD
Cost of Revenue
-8.4B USD
Gross Profit
36.6B USD
Operating Expenses
-19.6B USD
Operating Income
17B USD
Other Expenses
-6.5B USD
Net Income
10.6B USD
Fundamental Scores

LLY Profitability Score
Profitability Due Diligence

Eli Lilly and Co's profitability score is 75/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Positive Gross Profit
Exceptional ROE
Positive Operating Income
75/100
Profitability
Score

Eli Lilly and Co's profitability score is 75/100. The higher the profitability score, the more profitable the company is.

LLY Solvency Score
Solvency Due Diligence

Eli Lilly and Co's solvency score is 65/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Long-Term Solvency
Short-Term Solvency
65/100
Solvency
Score

Eli Lilly and Co's solvency score is 65/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

LLY Price Targets Summary
Eli Lilly and Co

Wall Street analysts forecast LLY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LLY is 1 015.76 USD with a low forecast of 707 USD and a high forecast of 1 249.5 USD.

Lowest
Price Target
707 USD
13% Downside
Average
Price Target
1 015.76 USD
25% Upside
Highest
Price Target
1 249.5 USD
54% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for LLY is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

LLY Insider Trading
Buy and sell transactions by insiders

LLY News

Other Videos
What is the Intrinsic Value of one LLY stock?

The intrinsic value of one LLY stock under the Base Case scenario is 375.83 USD.

Is LLY stock undervalued or overvalued?

Compared to the current market price of 813.48 USD, Eli Lilly and Co is Overvalued by 54%.

Back to Top